These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 21536742)

  • 1. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation.
    Hashimoto D; Chow A; Greter M; Saenger Y; Kwan WH; Leboeuf M; Ginhoux F; Ochando JC; Kunisaki Y; van Rooijen N; Liu C; Teshima T; Heeger PS; Stanley ER; Frenette PS; Merad M
    J Exp Med; 2011 May; 208(5):1069-82. PubMed ID: 21536742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
    Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
    Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-presenting cell-derived complement modulates graft-versus-host disease.
    Kwan WH; Hashimoto D; Paz-Artal E; Ostrow K; Greter M; Raedler H; Medof ME; Merad M; Heeger PS
    J Clin Invest; 2012 Jun; 122(6):2234-8. PubMed ID: 22585573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
    Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
    Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease.
    Sofi MH; Wu Y; Schutt SD; Dai M; Daenthanasanmak A; Heinrichs Voss J; Nguyen H; Bastian D; Iamsawat S; Selvam SP; Liu C; Maulik N; Ogretmen B; Jin J; Mehrotra S; Yu XZ
    J Clin Invest; 2019 May; 129(7):2760-2774. PubMed ID: 31045571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.
    Toubai T; Tamaki H; Peltier DC; Rossi C; Oravecz-Wilson K; Liu C; Zajac C; Wu J; Sun Y; Fujiwara H; Henig I; Kim S; Lombard DB; Reddy P
    J Immunol; 2018 Dec; 201(11):3443-3455. PubMed ID: 30389773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early myeloid-derived suppressor cells (HLA-DR
    Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
    Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation.
    Ross D; Jones M; Komanduri K; Levy RB
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1430-8. PubMed ID: 23819914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells.
    Tugues S; Amorim A; Spath S; Martin-Blondel G; Schreiner B; De Feo D; Lutz M; Guscetti F; Apostolova P; Haftmann C; Hasselblatt P; Núñez NG; Hottiger MO; van den Broek M; Manz MG; Zeiser R; Becher B
    Sci Transl Med; 2018 Nov; 10(469):. PubMed ID: 30487251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD.
    Sofi MH; Wu Y; Ticer T; Schutt S; Bastian D; Choi HJ; Tian L; Mealer C; Liu C; Westwater C; Armeson KE; Alekseyenko AV; Yu XZ
    JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33554953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
    Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
    Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
    Kumar S; Leigh ND; Cao X
    Front Immunol; 2018; 9():3003. PubMed ID: 30627129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function.
    Leigh ND; O'Neill RE; Du W; Chen C; Qiu J; Ashwell JD; McCarthy PL; Chen GL; Cao X
    J Immunol; 2017 Jul; 199(1):336-347. PubMed ID: 28550198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
    MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
    Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.